PARP Inhibitors for Ovarian Cancer - Advanced Cancer Care

Overview of PARP Inhibitors for Ovarian Cancer

PARP inhibitors block poly-ADP ribose polymerase enzymes that are crucial for DNA repair in cancer cells, particularly those with BRCA mutations or homologous recombination deficiency (HRD). This leads to synthetic lethality, where cancer cells cannot survive. Oral agents such as olaparib, niraparib, and rucaparib are used as maintenance therapy after platinum-based chemotherapy in patients with high-grade serous ovarian cancer, fundamentally changing treatment approaches for HRD-positive tumors.

Types of PARP Inhibitor Therapy

• •Olaparib (Lynparza)
  Used as a first-line maintenance therapy after a response to platinum chemotherapy, extending progression-free survival (PFS) from 13 months to 56 months in BRCA-mutated cases, as demonstrated in the SOLO-1 trial.
• •Niraparib (Zejula)
  Effective for patients regardless of BRCA status (as shown in the PRIMA trial) and suitable for all responders with advanced disease.
• •Rucaparib (Rubraca)
  Demonstrates strong efficacy in HRD tumors, with frontline approval based on data from the ATHENA-COM trial.

When is PARP Inhibitor Therapy Needed?

• •After First-Line Platinum Chemotherapy
  All patients with stage III/IV epithelial ovarian cancer who achieve a complete or partial response should receive PARP maintenance therapy, regardless of their germline BRCA status, as shown by the PAOLA-1 and PRIMA trials.
• •For Platinum-Sensitive Recurrent Disease
  Re-treatment with PARP monotherapy or in combination is beneficial for patients whose disease recurs more than six months after platinum therapy; the ARIEL3 trial indicated a 16-month PFS benefit.
• •For Maintenance After Bevacizumab
  Dual maintenance therapy (PARP + bevacizumab) optimizes PFS in HRD-positive tumors, with the PAOLA-1 trial showing a PFS of 37 months versus 17 months for single-agent therapy, establishing this approach as standard for high-risk frontline cases.

The Treatment Process

PARP inhibitor therapy involves daily oral dosing (tablets or capsules) for up to 2-3 years or until disease progression. Baseline genomic testing (Myriad myChoice HRD assay) confirms patient eligibility. Monthly monitoring includes a complete blood count (CBC) to check for anemia and thrombocytopenia (which occurs in 40-60% of patients), as well as liver function tests and creatinine levels. Dose reductions (from 300 mg to 200 mg BID) may be necessary to manage grade 3 or higher toxicities without affecting efficacy. Administration is typically outpatient, allowing patients to maintain their everyday activities.

Benefits and Risks of PARP Therapy

Get Your Free Cancer Diet Plan & Report Analysis Now on WhatsApp

Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.

Get My Free Plan on WhatsApp

India's First Cancer Care Management Platform

Free to start•Secure & private•No app download needed

Therapy has been shown to double or triple progression-free survival (PFS) among BRCA/HRD subgroups. Patients with BRCA mutations experience a 70% reduced risk of progression or death. This treatment also improves quality of life compared to continuous chemotherapy while delaying disease recurrence.

• •Nausea
  Occurs in approximately 75% of patients, typically low-grade and manageable with antiemetics.
• •Fatigue
  Reported by 65% of patients during the course of treatment.
• •Hematologic Effects
  Common issues include anemia (40%) and thrombocytopenia (30%). These are usually reversible with dose adjustments.
• •Rare Risks
  In rare cases (1-2%), myelodysplastic syndrome or acute myeloid leukemia may occur, requiring lifelong monitoring.

Aftercare and Recovery

To care for yourself after PARP inhibitor therapy for ovarian cancer, take medications consistently with a low-fat meal. Monitor your CBC weekly initially, and report any fever or unusual bruising immediately. Quarterly CA-125 tests or CT scans will help track your response. Supplementation with folate and vitamin B12 can help manage cytopenias, and it's important to avoid pregnancy due to the teratogenic effects of the treatment. High-protein nutrition can help maintain hemoglobin levels during therapy.

Why Choose Everhope for PARP Therapy?

Everhope Oncology offers comprehensive HRD/genomic profiling with rapid initiation of PARP therapy, oversight from a molecular tumor board for combination strategies, and IV nutritional support to prevent treatment delays due to cytopenias.